Article Text

Download PDFPDF

77 Single institution outcomes for cervical cancer patients treated with palliative systemic anti cancer therapy
  1. C Cotronei1,
  2. A Stillie2 and
  3. M Zahra2
  1. 1University of Edinburgh, UK
  2. 2Western General Hospital Edinburgh Cancer Centre, Edinburgh, UK


Aim Bevacizumab, in combination with chemotherapy, has been implemented as first line treatment of patients with metastatic cervical cancer since 2015. This is a single institution review to evaluate the overall survival (OS) and progression free survival (PFS) for patients with advanced cervical cancer treated with palliative systemic anti cancer therapy (SACT) over a 5-year period from 2015-2020.

Methodology Patient records were reviewed retrospectively for all cervical cancer patients who received palliative SACT in a single institution between 2015-2020. Patient demographics, previous treatment for cervical cancer (if applicable), palliative SACT regimen received, toxicities, and outcome data were recorded. OS and PFS were calculated for the whole cohort and for the following subgroups: patients treated with Bevacizumab in combination with palliative chemotherapy; patients treated with chemotherapy alone. Toxicities were recorded by Common Toxicity Criteria (CTC).

Result(s)*52 patients received palliative SACT during the 5-year period following a diagnosis of metastatic cervical cancer. The median age was 51 (range 25-76). The majority of patients had a squamous cell histology (75%). 40 patients received Bevacizumab in combination with chemotherapy, 12 were treated with chemotherapy alone due to comorbidities. The median OS for the whole patient cohort was 64 weeks and PFS was 45 weeks. Patients who received bevacizumab in combination with chemotherapy had a median OS of 76 weeks compared to 50 weeks in the chemotherapy only subgroup. Grade 1 and 2 toxicites were comparable in patients receiving chemotherapy alone and those treated with Bevacizumab. 10% of patients in the cohort receiving bevacizumab developed a thromboembolic event compared with 5.5% in the chemotherapy only cohort.

Conclusion*Results from this study of real world data are comparable with the published data. The results support the continued use of Bevacizumab, in combination with chemotherapy, in our patient population as the combination regimen improves OS with acceptable toxicties.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.